CHAPEL HILL, N.C., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2014 financial results after the close of U.S. financial markets on October 29, 2014. Cempra management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.cempra.com and will be archived there for 30 days. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 22058330.
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin also recently entered a Phase 3 clinical trial for uncomplicated Neisseria gonorrhea and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which completed a Phase 2 clinical trial for prosthetic joint infections. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.
CONTACT: Mark W. Hahn Chief Financial Officer 919-313-6601 Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 firstname.lastname@example.org Media Contacts: Russo Partners, LLC Robert E. Flamm, Ph.D. (212) 845-4226 email@example.com Lena Evans (212) 845-4262 firstname.lastname@example.orgSource:Cempra, Inc.